文献速递系统性红斑狼疮

羟氯喹依从性改善系统性红斑狼疮患者的长期生存

Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

本研究利用台湾全民健康保险研究数据库的前瞻性SLE队列,按诊断后第一年是否处方HCQ分为HCQ组与对照组,经倾向评分匹配后每组2287例。平均随访7.6年,HCQ组死亡169例(7.4%),对照组248例(10.8%),HCQ组死亡风险低于对照组(HR=0.68;95%CI:0.56,0.82)。亚组分析显示生存保护效应与HCQ依从性相关。

要点

  • HCQ组全因死亡风险低于对照组(HR=0.68;95%CI:0.56,0.82)。
  • 平均随访7.6年,HCQ组死亡169例(7.4%),对照组248例(10.8%)。
  • 亚组分析显示生存保护效应与HCQ依从性相关。

核心结论

  • 接受HCQ治疗的SLE患者全因死亡率低于未接受HCQ者,且生存获益可因HCQ依从性而增强。

研究设计与样本

  • 前瞻性SLE队列研究,使用台湾全民健康保险研究数据库数据。
  • 按SLE诊断后第一年内是否处方HCQ分为HCQ组与对照组,主要结局为入组后1年死亡率。
  • 亚组分析按第一年药物持有率(MPR)分为未使用者、MPR<40%、40%⩽MPR<80%和MPR⩾80%亚组。
  • 共12443例患者符合分析条件,经倾向评分匹配后每组纳入2287例。

主要发现

  • 平均随访7.6年,HCQ组死亡169例(7.4%),对照组死亡248例(10.8%)。
  • HCQ组死亡风险低于对照组(HR=0.68;95%CI:0.56,0.82)。
  • 亚组分析显示生存保护效应与HCQ依从性相关。

关键数值与推荐

  • HCQ组死亡169例(7.4%),对照组死亡248例(10.8%)。
  • HCQ组较对照组的死亡风险HR=0.68(95%CI:0.56,0.82)。
  • MPR亚组划分:未使用者、MPR<40%、40%⩽MPR<80%、MPR⩾80%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: HCQ, which is known to decrease SLE activity, may have a protective effect on survival, but this has not been proven in Asia. This study aimed to determine whether HCQ treatment is associated with increased survival in patients with SLE. METHODS: We designed this prospective SLE cohort study using data from the Taiwan National Health Insurance Research Database. The participants were divided into HCQ and control groups according to whether HCQ was prescribed during the first year after an SLE diagnosis. The primary outcome was mortality 1 year after inclusion. In the subgroup analysis, these participants were divided based on medication possession ratio (MPR) in the first year into non-users, MPR <40%, 40% ⩽ MPR < 80% and MPR ⩾80% subgroups to explore the relationship between survival and HCQ adherence. RESULTS: A total of 12 443 patients were eligible for the analysis. After propensity score matching, we included 2287 patients in each group. During a mean follow-up of 7.6 years, there were 169 events in the HCQ group (7.4%) and 248 events in the control group (10.8%). The risk of mortality in the HCQ group was lower than that in the control group (hazard ratio = 0.68; 95% CI: 0.56, 0.82). The subgroup analysis revealed that the survival protective effect was associated with HCQ adherence. CONCLUSION: Patients with SLE who received HCQ had lower mortality rates due to any cause than those who did not. The survival benefit could be augmented by HCQ adherence.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hsu CY, Lin YS, Cheng TT, et al. Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. Rheumatology (Oxford). 2018. PMID: 29931367. doi:10.1093/rheumatology/key167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。